Evidence map›Paper›PMID 39640604›Full record

ArticleHeliyon2024

Oxidative stress gene signature construction to identify subtypes and prognosis of patients with lung adenocarcinoma.

Lan Li, Rujia Qin, Xuefeng Wang, Ke Cao, Fei Lu, Zhengting Chen, Jingyan Gao, Linbo Qiu, Sisong Shu, Han Lu and 2 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lan LiDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Rujia QinDepartment of oncology, Northern Jiangsu People's Hospital, Yangzhou 225000, PR China.
Xuefeng WangDepartment of Hepatobiliary Surgery, Xiantao First People's Hospital, Xiantao 433000, Hubei, China.
Ke CaoDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Fei LuDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Zhengting ChenDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Jingyan GaoDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Linbo QiuDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Sisong ShuDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Han LuDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Li ChangDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.
Wenhui LiDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital/Peking University Cancer Hospital Yunnan, Kunming 650118, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although oxidative stress and malignancies are intimately connected, it is unknown how lung adenocarcinoma (LUAD) is affected by oxidative stress response-related genes (OSRGs).Our goal in this work was to create a genetic signature based on OSRGs that might both predict prognosis and hint to potential treatment options for LUAD. Methods: Clinicopathological and transcriptome information on LUAD patients was obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A model for predicting risk was created using LASSO regression. The TCGA, GSE72094, and GSE41271 cohorts all demonstrated the risk model's prediction ability. Immune cell infiltration was measured using the CIBERSORT method, and the TIDE platform was implemented to evaluate the therapeutic efficacy of immune checkpoint inhibition (ICI). Chemotherapy sensitivity was predicted using drug activity data by the Genomics of Drug Sensitivity. An investigation into gene expression was conducted using qRT-PCR. CCK-8 and transwell assays were employed to look into how DKK1 affected the migration and proliferation of LUAD cells. Results: A gene signature consisting of Conclusion: Our thorough transcriptome study of OSRGs generated a biological framework effective in forecasting outcome and responsiveness to therapy in LUAD patients.

Indexed as

Differentially expressed genesDrug sensitivityLung adenocarcinomaOxidative stress response-related genesPrognosis

Identifiers

PMID39640604
PMCPMC11619975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.